PTPN6 and colorectal carcinoma: This induction was not seen in D61A and dN1 mutant SHP-1-expressing CRC cells, indicating that regorafenib-enhanced SHP-1 activity is due to its docking potential between the inhibitory N-SH2 domain and catalytic PTP domain of SHP-1, which directly relieves the autoinhibition of SHP-1.